AMGN
Price
$344.57
Change
+$3.46 (+1.01%)
Updated
Nov 26 closing price
Capitalization
185.54B
68 days until earnings call
Intraday BUY SELL Signals
GILD
Price
$127.51
Change
+$0.39 (+0.31%)
Updated
Nov 26 closing price
Capitalization
158.2B
75 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMGN vs GILD

Header iconAMGN vs GILD Comparison
Open Charts AMGN vs GILDBanner chart's image
Amgen
Price$344.57
Change+$3.46 (+1.01%)
Volume$2.33M
Capitalization185.54B
Gilead Sciences
Price$127.51
Change+$0.39 (+0.31%)
Volume$5.83M
Capitalization158.2B
AMGN vs GILD Comparison Chart in %
AMGN
Daily Signal:
Gain/Loss:
GILD
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AMGN vs. GILD commentary
Nov 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a StrongBuy and GILD is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 27, 2025
Stock price -- (AMGN: $344.57 vs. GILD: $127.51)
Brand notoriety: AMGN and GILD are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 93% vs. GILD: 77%
Market capitalization -- AMGN: $185.54B vs. GILD: $158.2B
AMGN [@Pharmaceuticals: Major] is valued at $185.54B. GILD’s [@Pharmaceuticals: Major] market capitalization is $158.2B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $988.41B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $101.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 3 FA rating(s) are green whileGILD’s FA Score has 4 green FA rating(s).

  • AMGN’s FA Score: 3 green, 2 red.
  • GILD’s FA Score: 4 green, 1 red.
According to our system of comparison, GILD is a better buy in the long-term than AMGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 5 TA indicator(s) are bullish while GILD’s TA Score has 3 bullish TA indicator(s).

  • AMGN’s TA Score: 5 bullish, 4 bearish.
  • GILD’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, GILD is a better buy in the short-term than AMGN.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а +1.35% price change this week, while GILD (@Pharmaceuticals: Major) price change was -0.44% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.85%. For the same industry, the average monthly price growth was +3.30%, and the average quarterly price growth was +17.38%.

Reported Earning Dates

AMGN is expected to report earnings on Feb 03, 2026.

GILD is expected to report earnings on Feb 10, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+1.85% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMGN($186B) has a higher market cap than GILD($158B). AMGN has higher P/E ratio than GILD: AMGN (26.38) vs GILD (19.74). GILD YTD gains are higher at: 40.971 vs. AMGN (37.210). AMGN has higher annual earnings (EBITDA): 16.5B vs. GILD (11B). GILD has less debt than AMGN: GILD (24.9B) vs AMGN (56.2B). AMGN has higher revenues than GILD: AMGN (36B) vs GILD (28.9B).
AMGNGILDAMGN / GILD
Capitalization186B158B118%
EBITDA16.5B11B150%
Gain YTD37.21040.97191%
P/E Ratio26.3819.74134%
Revenue36B28.9B125%
Total Cash923MN/A-
Total Debt56.2B24.9B226%
FUNDAMENTALS RATINGS
AMGN vs GILD: Fundamental Ratings
AMGN
GILD
OUTLOOK RATING
1..100
2122
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
16
Undervalued
PROFIT vs RISK RATING
1..100
207
SMR RATING
1..100
10028
PRICE GROWTH RATING
1..100
1521
P/E GROWTH RATING
1..100
78100
SEASONALITY SCORE
1..100
6565

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GILD's Valuation (16) in the Biotechnology industry is in the same range as AMGN (17). This means that GILD’s stock grew similarly to AMGN’s over the last 12 months.

GILD's Profit vs Risk Rating (7) in the Biotechnology industry is in the same range as AMGN (20). This means that GILD’s stock grew similarly to AMGN’s over the last 12 months.

GILD's SMR Rating (28) in the Biotechnology industry is significantly better than the same rating for AMGN (100). This means that GILD’s stock grew significantly faster than AMGN’s over the last 12 months.

AMGN's Price Growth Rating (15) in the Biotechnology industry is in the same range as GILD (21). This means that AMGN’s stock grew similarly to GILD’s over the last 12 months.

AMGN's P/E Growth Rating (78) in the Biotechnology industry is in the same range as GILD (100). This means that AMGN’s stock grew similarly to GILD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNGILD
RSI
ODDS (%)
Bearish Trend 1 day ago
58%
Bearish Trend 7 days ago
55%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
48%
Bearish Trend 1 day ago
38%
Momentum
ODDS (%)
Bullish Trend 1 day ago
60%
Bullish Trend 1 day ago
64%
MACD
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
70%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 1 day ago
43%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
61%
Advances
ODDS (%)
Bullish Trend 10 days ago
57%
Bullish Trend 1 day ago
62%
Declines
ODDS (%)
Bearish Trend 8 days ago
51%
Bearish Trend 11 days ago
46%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
60%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
46%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
AMGN
Daily Signal:
Gain/Loss:
GILD
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MMSC24.070.29
+1.23%
First Trust Multi-Manager Sm Cp Opps ETF
QUVU27.410.20
+0.73%
Hartford Quality Value ETF
IUSG167.811.14
+0.68%
iShares Core S&P US Growth ETF
WDI14.280.02
+0.14%
Western Asset Diversified Income Fund
FIRS23.08N/A
N/A
FIRE Funds Wealth Builder ETF

AMGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMGN
1D Price
Change %
AMGN100%
+3.07%
PFE - AMGN
56%
Loosely correlated
-0.04%
BIIB - AMGN
56%
Loosely correlated
-0.01%
NVS - AMGN
55%
Loosely correlated
+0.14%
BMY - AMGN
54%
Loosely correlated
+0.41%
ABBV - AMGN
53%
Loosely correlated
-1.79%
More